Merck
  • Home
  • Search Results
  • p53 Loss in Breast Cancer Leads to Myc Activation, Increased Cell Plasticity, and Expression of a Mitotic Signature with Prognostic Value.

p53 Loss in Breast Cancer Leads to Myc Activation, Increased Cell Plasticity, and Expression of a Mitotic Signature with Prognostic Value.

Cell reports (2019-01-17)
Angela Santoro, Thalia Vlachou, Lucilla Luzi, Giorgio Melloni, Luca Mazzarella, Errico D'Elia, Xieraili Aobuli, Cristina Elisabetta Pasi, Linsey Reavie, Paola Bonetti, Simona Punzi, Lucia Casoli, Arianna Sabò, Maria Cristina Moroni, Gaetano Ivan Dellino, Bruno Amati, Francesco Nicassio, Luisa Lanfrancone, Pier Giuseppe Pelicci
ABSTRACT

Loss of p53 function is invariably associated with cancer. Its role in tumor growth was recently linked to its effects on cancer stem cells (CSCs), although the underlying molecular mechanisms remain unknown. Here, we show that c-myc is a transcriptional target of p53 in mammary stem cells (MaSCs) and is activated in breast tumors as a consequence of p53 loss. Constitutive Myc expression in normal mammary cells leads to increased frequency of MaSC symmetric divisions, extended MaSC replicative-potential, and MaSC-reprogramming of progenitors, whereas Myc activation in breast cancer is necessary and sufficient to maintain the expanding pool of CSCs. Concomitant p53 loss and Myc activation trigger the expression of 189 mitotic genes, which identify patients at high risk of mortality and relapse, independently of other risk factors. Altogether, deregulation of the p53:Myc axis in mammary tumors increases CSC content and plasticity and is a critical determinant of tumor growth and clinical aggressiveness.